OUR PUBLICATIONS

 
logo-color@3x.png

CHARCOT-MARIE-TOOTH DISEASE PUBLICATIONS

Treatment patterns for Charcot-Marie-Tooth disease in the UK and US: insights from a digital real-world observational study” Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (EAN, 2019)

“Care standards for Charcot-Marie-Tooth disease in the UK and US: insights from a digital real-world observational study” Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (EAN, 2019)

“Diversity in the Charcot-Marie-Tooth disease population in the UK and US: insights from a digital real-world observational study” Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (EAN, 2019)

“Digitally assessed real-world diversity in people with Charcot-Marie-Tooth disease in the UK and US”, Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (PNS, 2019)

• “Digitally assessed patient-reported real-world care standards for Charcot-Marie-Tooth disease in the UK and US , Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (PNS, 2019) 

Patient-reported real-world care standards for Charcot-Marie-Tooth disease in the UK and US assessed using a digital ‘bring your own device’ platform” Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (ISPOR US, 2019)

Patient-reported real-world treatment patterns for Charcot-Marie-Tooth disease in the UK and US assessed using a digital ‘bring your own device’ platform” Ziemssen T, Attarian S, Thomas FP, Moore A, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Bagshaw E, Kousoulakou H, Larkin M (ISPOR US, 2019)

Development of a digital app and innovative recruitment for an international real-world observational study in Charcot-Marie-Tooth disease” Ziemssen T, Attarian S, Thomas FP, Tanesse D, Paoli X, Bertrand V, Boutalbi Y, Kousoulakou H, Larkin M (ISPOR Europe, 2018)

 
Digital Registry no background.png

MELANOMA PUBLICATIONS

Adverse events associated with immunotherapies used in the treatment of stage 3 and 4 melanomaLlewellyn S, Åkesson C, Kousoulakou H, Larkin M (ISPOR US, 2019)

Patient-reported real-world treatment patterns for melanoma in the UK measured using a digital ‘bring your own device’ platform” Larkin J, Cannon D, Nuttall G, Au L, Hunter N, Spain L, Turajlic S, Åkesson C, Llewellyn S, Nixon A, Kousoulakou H, Larkin M, Wiseman T (ISPOR US, 2019)

Real-world HRQL in patients with melanoma derived using  a digital ‘Bring-Your-Own-Device’ platform”, Larkin J, Nuttall G, Cannon D, Au L, Spain L, Hunter N, Turajlic S, Nixon A, Kousoulakou H, Larkin M, Wiseman T (PROMS Conference, 2018)

Taking the burden out of symptom reporting in patients with melanoma using a digital real-world evidence platform”. Au L, Nuttall G, Cannon D, Spain L, Hunter N, Turajlic S, Nixon A, Kousoulakou HLarkin M, Larkin J, Wiseman T (ISPOR US, 2018)

“Real-world EQ-5D-5L utility values in patients with melanoma derived using a digital ‘Bring-Your-Own-Device’ platform”. Larkin J, Nuttall G, Cannon D, Au L, Spain L, Hunter N, Turajlic S, Nixon A, Kousoulakou H, Larkin M, Wiseman T (ISPOR US, 2018)

Digital real-world evidence platform: taking the burden out of melanoma pain reporting”. Larkin M, Nixon A, Spinage J, Williams H (ISPOR EU, 2017)